Form 4 for NMRA Neumora Therapeutics, Inc.
Accepted 2023-09-19 00:00:00 ET · period of report 2023-09-19 · accession 0001610717-23-000290 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-09-19 | 2023-09-19 | NMRA | Gosebruch Henry O | Pres, CEO, Dir | P - Purchase | $12.62 | +15.0K | 15.0K | New | +$189.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-19 | P | A | 15,000 | $12.62 | 15,000 | I See Footnote | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.465 to $12.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. (F2) Shares held by HG4KYC TRUST, of which Reporting Person is trustee. |